Assignee: Crucell Holland B.V.

Location: Leiden, NL
No. of applications: 64

Application No.	Application Title	Issue Date
20110150930	Recombinant viral-based malaria vaccines Described are vaccines against malarial infections, which are based on recombinant viral vectors, such as alpha viruses, adenoviruses, or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such ...	06/23/2011
20100311160	Cultures of E1-immortalized cells and processes for culturing the same to increase product yields therefrom Provided are processes for culturing cells derived from embryonic retinoblast cells immortalized by adenovirus E1 sequences, such as PER.C6® cells, to improve product yields from such cells. Feed strategies for such cells and cultures with very high cell densiti...	12/09/2010
20100310572	Binding molecules capable of neutralizing rabies virus and uses thereof Provided are binding molecules that specifically bind to rabies virus and are capable of neutralizing the virus. Further provided are nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or produ...	12/09/2010
20100221774	Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby Provided are compositions comprising one or more isoforms of an erythropoietin (“EPO”) comprising glycans linked thereto, wherein the glycans have Lewis x structures and on average at least six sialic acid moieties per EPO molecule. Further provided are methods for ...	09/02/2010
20100184671	Binding molecules for the treatment of myeloid cell malignancies Provided is a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods...	07/22/2010
20100172928	Recombinant viral-based malaria vaccines The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infe...	07/08/2010
20100172917	Binding molecules against SARS-coronavirus and uses thereof Described are binding molecules that specifically bind to SARS-CoV, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules, and methods of identifying or producing the binding molecules. The binding molecules are capable of ...	07/08/2010
20100144620	COMPLEMENTATION OF FACTOR XI DEFICEINCY BY FACTOR V MUTANTS Described are methods for preventing and/or treating bleeding in a subject with Factor XI deficiency, such as hemophilia C, which methods comprise administering to the subject APC-resistant Factor V....	06/10/2010
20100062512	PURIFICATION OF FACTOR XI The invention provides methods for purifying blood coagulation Factor XI from biological fluids, the methods comprising a step of hydrophobic charge induction chromatography (HCIC)....	03/11/2010
20100041022	Novel assay for the separation and quantification of hemagglutinin antigens Described are methods for separating hemagglutinin (HA) antigens, comprising the steps of applying a reduced and derivatized antigen preparation comprising solubilized HA antigens and a detergent in a pH controlled solution, on a Reversed-Phase High-Performance Liquid C...	02/18/2010
20100034774	Serotype of adenovirus and uses thereof Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tra...	02/11/2010
20100015176	Settings for recombinant adenoviral-based vaccines The present invention provides new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, the invention provides new assays to determine the best regimen for ap...	01/21/2010
20090324645	Production of vaccines Means and methods for producing mammalian viruses, the method comprising infecting a culture of immortalized human cells with a virus, incubating the culture infected with virus to propagate the virus under conditions that permit growth of the virus, and to form a virus...	12/31/2009
20090285879	Malaria prime/boost vaccines Described are vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from Plasmodium falciparum and purified recombinant protein vaccines such as RTS,S, in...	11/19/2009
20090253207	Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells A gene delivery vehicle having been provided with at least a tissue tropism for cells selected from the group of smooth muscle cells, endothelial cells, and/or liver cells. The tissue tropism is generally provided by a virus capsid, such as one comprising protein fragme...	10/08/2009
20090239287	Production of vaccines Means and methods are provided for the production of mammalian viruses comprising: infecting a culture of immortalized human cells with the virus, incubating the culture infected with virus to propagate the virus under conditions that permit growth of the virus, and to ...	09/24/2009
20090170164	Recombinant protein production in a human cell Methods and compositions for the production of recombinant proteins in a human cell line. The methods and compositions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, for example,...	07/02/2009
20090130652	Optimization of West Nile Virus Antibodies The invention relates to the production of binding molecules. In particular, the invention relates to methods for producing binding molecules having an improved functionality of interest....	05/21/2009
20090123989	VIRUS PURIFICATION USING ULTRAFILTRATION The invention provides a method for the purification, of a virus comprising a step of ultrafiltration wherein the reteniate contains the virus, wherein back pressure of at least 5 kPa is applied on the permeate side. The invention also provides a method for purification...	05/14/2009
20090017523	Virus purification methods Provided is a method for purifying a virus from a host cell, the method comprising: a) culturing host cells, b) infecting the host cells with a virus, c) treating the cell culture with nuclease, and d) lysing the host cells to provide a lysate comprising the virus. The ...	01/15/2009
20090017068	Vaccines against West Nile Virus Described are vaccines containing (whole-inactivated) West Nile Viruses and/or West Nile viral proteins derived therefrom, produced on human cells, wherein the human cells comprise a sequence encoding at least one early region-1 (E1) gene product of an adenovirus. The c...	01/15/2009
20080227199	Method for simultaneous production of multiple proteins; vectors and cells for use therein Described is the production of proteins in a host cell. More specifically, described are methods for improving expression of two or more proteins in a cell or host cell. The methods are suited for production of, for example, recombinant antibodies that can be used in ph...	09/18/2008
20080227151	Method for simultaneous production of multiple proteins; vectors and cells for use therein Described is the production of proteins in a host cell. Even more specifically, described are methods for improving expression of two or more proteins in a cells or host cell. The methods are suited for production of, for example, recombinant antibodies that can be used...	09/18/2008
20080220014	Recombinant viral-based malaria vaccines The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infe...	09/11/2008
20080206837	Stable adenoviral vectors and methods for propagation thereof Provided are methods and means to increase the stability and/or the packaging capacity of recombinant adenoviruses, by overexpression of pIX in an adenoviral packaging cell, by retaining at least a part of the E1B-55K region in the recombinant adenoviral vector or by re...	08/28/2008
20080199939	Adenoviral Vectors and Uses Thereof The present invention relates to recombinant adenoviral vectors based on adenoviruses that encounter pre-existing immunity in a minority of the human population and which harbour a chimeric capsid. The chimeric capsid comprises fiber proteins that have at least the knob...	08/21/2008
20080199917	Means and methods for producing adenovirus vectors The invention relates to methods and means for producing adenoviral vectors on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenoviral vector and wherein the E4-orf6 gene product is compatibl...	08/21/2008
20080199433	Complementing cell lines A packaging cell line that complements recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells that are transformed by adenovirus E1 sequences either operatively li...	08/21/2008
20080171018	Serotype of adenovirus and uses thereof Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tra...	07/17/2008
20080166767	Efficient production of F(ab')2 fragments in mammalian cells The present invention provides immortalized eukaryotic cells and methods useful for the production of immunologically active bivalent antibody fragments, such as F(ab′)2 fragments. The methods and cells of the invention result in a desirable ratio of bivalent to monov...	07/10/2008
20080153083	Settings for recombinant adenoviral-based vaccines The present invention provides new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, the invention provides new assays to determine the best regimen for ap...	06/26/2008
20080138901	Packaging systems for human recombinant adenovirus to be used in gene therapy Presented are ways to address the problem of replication-competent adenovirus in adenoviral production for use with, for example, gene therapy. Packaging cells having no overlapping sequences with a selected vector are suited for large scale production of recombinant ad...	06/12/2008
20080131461	Malaria Prime/Boost Vaccines The invention relates to novel vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from Plasmodium falciparum and purified recombinant protein vaccines ...	06/05/2008
20080124803	cDNA Corresponding to the antigenome of nonsegmented negative stranded RNA viruses and process for the production of such viruses The present invention relates, in general, to a methodology for the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in s...	05/29/2008
20080032922	Methods and means for producing proteins with predetermined post-translational modifications Described are methods for identifying, selecting, and obtaining mammalian cells capable of producing proteinaceous molecules having predetermined post-translational modifications, wherein the post-translational modifications are brought about by the mammalian cell in wh...	02/07/2008
20070287163	Methods for Diagnosis of Acute Myeloid Leukemia The present invention provides a new marker for AML, binding molecules that specifically bind to the new marker, nucleic acid molecules encoding the binding molecules and compositions comprising the binding molecules. The binding molecules capable of specifically bindin...	12/13/2007
20070231860	Over-expression of enzymes involved in post-translational protein modifications in human cells Methods for producing and/or propagating virus particles that are present in a virus isolate obtained from an infected subject by contacting a host cell with a virus particle and culturing the cell under conditions conducive to propagation of the virus particle are disc...	10/04/2007
20070128217	Antigenic peptides of SARS coronavirus and uses thereof The present invention pertains to antigenic peptides of SARS-CoV and their use in diagnostic test methods and in the treatment of condition resulting from SARS-CoV. Furthermore, this invention provides antibodies capable of specifically recognizing the peptides of the i...	06/07/2007
20070117742	Methods and means for producing proteins with predetermined post-translational modifications Described are methods for identifying, selecting, and obtaining mammalian cells capable of producing proteinaceous molecules having predetermined post-translational modifications, wherein the post-translational modifications are brought about by the mammalian cell in wh...	05/24/2007
20070088156	Recombinant viral-based malaria vaccines The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infe...	04/19/2007

«First «Previous1 2 Next»Last»

PatentStorm

Bizarre Patents

PatentStorm News

Assignee: Crucell Holland B.V.